Cargando…

Editorial to implantable cardioverter defibrillator and cardiac resynchronization therapy use in New Zealand (ANZACS‐QI 33)

Detalles Bibliográficos
Autor principal:	Minamiguchi, Hitoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011852/ https://www.ncbi.nlm.nih.gov/pubmed/32071635 http://dx.doi.org/10.1002/joa3.12263

Ejemplares similares

Implantable cardioverter defibrillator and cardiac resynchronization therapy use in New Zealand (ANZACS‐QI 33)
por: Foo, Fang Shawn, et al.
Publicado: (2019)

Manual vs. automatic capture management in implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators
por: Murgatroyd, Francis D., et al.
Publicado: (2010)

Loss of cardiac resynchronization therapy in a patient with a biventricular implantable cardioverter-defibrillator
por: Alasti, Mohammad, et al.
Publicado: (2017)

Association Between Subcutaneous Implantable Cardioverter Defibrillator Preimplantation Screening and the Response to Cardiac Resynchronization Therapy
por: Jing, Ran, et al.
Publicado: (2020)

Economic analysis of remote monitoring in patients with implantable cardioverter defibrillators or cardiac resynchronization therapy defibrillators in the Trento area, Italy
por: Marini, Massimiliano, et al.
Publicado: (2023)

The economic impact of remote control in patients with implantable cardioverter defibrillators or cardiac resynchronization therapy defibrillators: single center experience
por: Marini, M, et al.
Publicado: (2023)

One Indication for an Extravascular Cardiac Resynchronization Therapy Defibrillator: Lessons from a Combination Therapy Case with Epicardial Cardiac Resynchronization Therapy and a Subcutaneous Implantable Cardioverter Defibrillator
por: Ishii, Natsuko, et al.
Publicado: (2021)

The impact of a national COVID-19 lockdown on acute coronary syndrome hospitalisations in New Zealand (ANZACS-QI 55)
por: Chan, Daniel ZL., et al.
Publicado: (2020)

The Impact of a National COVID-19 Lockdown on Acute Coronary Syndrome Hospitalisations in New Zealand: an ANZACS-QI study
por: Chan, D., et al.
Publicado: (2021)

Primary prevention implantable cardioverter defibrillator in cardiac resynchronization therapy recipients with advanced chronic kidney disease
por: Goldenberg, Ido, et al.
Publicado: (2023)

Remote Monitoring of Implantable Cardioverter Defibrillator
por: Reynolds, Dwight W, et al.
Publicado: (2006)

Inappropriate Shock Delivered By Implantable Cardioverter Defibrillator - Cardiac Resynchronization Therapy (ICD-CRT) Due To Myopotential Oversensing
por: Barakpour, Hamid, et al.
Publicado: (2009)

A review of economic evaluation models for cardiac resynchronization therapy with implantable cardioverter defibrillators in patients with heart failure
por: Tomini, F., et al.
Publicado: (2016)

The economic impact of battery longevity in implantable cardioverter-defibrillators for cardiac resynchronization therapy: the hospital and healthcare system perspectives
por: Landolina, Maurizio, et al.
Publicado: (2017)

Prehospital identification of ST-segment elevation myocardial infarction and mortality (ANZACS-QI 61)
por: Liao, Becky Yi-Wen, et al.
Publicado: (2022)

The importance of leadless pacemaker positioning in relation to subcutaneous implantable cardioverter-defibrillator sensing in completely leadless cardiac resynchronization and defibrillation systems
por: Elliott, Mark K., et al.
Publicado: (2021)

Importance of Implantable Cardioverter‐Defibrillator Back‐Up in Cardiac Resynchronization Therapy Recipients: A Systematic Review and Meta‐Analysis
por: Barra, Sérgio, et al.
Publicado: (2015)

Association left ventricular lead and ventricular arrhythmias after upgrade to cardiac resynchronization therapy in patients with implantable cardioverter defibrillators
por: Kawamura, Mitsuharu, et al.
Publicado: (2019)

Premature ventricular contractions in patients with an implantable cardioverter defibrillator cardiac resynchronization therapy device: Results from the UMBRELLA registry
por: Akerström, Finn, et al.
Publicado: (2020)

Cost-effectiveness of cardiac resynchronization therapy plus an implantable cardioverter-defibrillator in patients with heart failure: a systematic review
por: Teimourizad, Abedin, et al.
Publicado: (2021)

Cardiac Sarcoidosis: Indications for Implantable Cardioverter-Defibrillator Therapy
por: Yalta, Kenan, et al.
Publicado: (2022)

The first cardioverter defibrillator implanted in Central Africa
por: Cabral, Tantchou Tchoumi Jacques, et al.
Publicado: (2016)

Characteristics of Cardiac Memory in Patients with Implanted Cardioverter-defibrillators: The Cardiac Memory with Implantable Cardioverter-defibrillator (CAMI) Study
por: Haq, Kazi T., et al.
Publicado: (2021)

Left bundle branch pacing–optimized implantable cardioverter-defibrillator (LOT-ICD) for cardiac resynchronization therapy: A pilot study
por: Ponnusamy, Shunmuga Sundaram, et al.
Publicado: (2022)

Effect of cardiac resynchronization therapy with implantable cardioverter defibrillator versus cardiac resynchronization therapy with pacemaker on mortality in heart failure patients: results of a high-volume, single-centre experience
por: Kutyifa, Valentina, et al.
Publicado: (2014)

Role of Implantable Cardioverter Defibrillators in the Treatment of Hypertrophic Cardiomyopathy
por: Ghosh, Joydeep, et al.
Publicado: (2005)

Implantable cardioverter-defibrillators /
Publicado: (1994)

Implantation of left atrial-ventricular epicardial pacemaker system and subcutaneous implantable cardioverter-defibrillator in a single setting: The “extravascular” cardiac resynchronization therapy
por: Sharma, Saumya, et al.
Publicado: (2019)

Implantation of a Resynchronization Implantable Cardioverter Defibrillator in a Patient with Persistent Left Superior Vena Cava
por: Antonelli, Dante, et al.
Publicado: (2007)

Trends in the use of implantable cardioverter‐defibrillator and cardiac resynchronization therapy device in advancing age: Analysis of the Japan cardiac device treatment registry database
por: Yokoshiki, Hisashi, et al.
Publicado: (2020)

Gulf Implantable Cardioverter-defibrillator Registry Reflects Advanced Cardiac Care in the Arab Gulf
por: Albinali, Hajar A.
Publicado: (2015)

Estimating the economic impact of acute coronary syndrome in New Zealand over time (ANZACS-QI 64): a national registry-based cost burden study
por: Lee, Peter, et al.
Publicado: (2022)

Longevity of implantable cardioverter-defibrillators for cardiac resynchronization therapy in current clinical practice: an analysis according to influencing factors, device generation, and manufacturer
por: Landolina, Maurizio, et al.
Publicado: (2015)

Successful Treatment of an Infant with Left Ventricular Noncompaction Presenting with Fatal Ventricular Arrhythmia Treated with Cardiac Resynchronization Therapy and an Implantable Cardioverter Defibrillator
por: Kimura, Masato, et al.
Publicado: (2018)

Impact of COVID-19 lockdown in patients with implantable cardioverter and cardiac resynchronization therapy defibrillators: insights from daily remote monitoring transmissions
por: Mascioli, Giosuè, et al.
Publicado: (2021)

One-Year Mortality in Patients Undergoing an Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy Pulse Generator Replacement: Identifying Patients at Risk
por: Feijen, Michelle, et al.
Publicado: (2023)

Association of Guideline-Based Medical Therapy with Malignant Arrhythmias and Mortality among Heart Failure Patients Implanted with Cardioverter Defibrillator (ICD) or Cardiac Resynchronization-Defibrillator Device (CRTD)
por: Hasin, Tal, et al.
Publicado: (2021)

Should mechanical dyssynchrony be assessed in patients with implantable cardioverter-defibrillators?
por: Boogers, Mark J., et al.
Publicado: (2010)

Efficacy and Safety of Transvenous Lead Extraction at the Time of Upgrade from Pacemakers to Cardioverter-Defibrillators and Cardiac Resynchronization Therapy
por: Stefańczyk, Paweł, et al.
Publicado: (2022)

Routine exercise testing could not predict T‐wave oversensing in a patient after a subcutaneous implantable cardioverter‐defibrillator implant
por: Konishi, Shozo, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_kflsbr4ijl8lhnrttun0ghdq5a